Sharechat Logo

Genesis Research in talks with new investor, raises $446,278 in placement

Tuesday 15th June 2010

Text too small?

Genesis Research, which suspended its New Zealand operations last month after running out of cash, said it has raised $446,278 in a placement and is in talks with a new investor about future research and development.

The biotechnology company sold 7.4 million shares at 6 cents apiece, the same price as its last capital raising in March, it said in a statement today. The placement would be completed in the next two weeks.

Genesis key gene silencing technology is owned by Solirna Biosciences, a joint venture with a Japanese investment group that put up $500,000 and promised a further such sum if certain milestones were met. Today, Genesis said it was continuing talks with a number of groups about investing in Solirna.

Other assets, namely its Real Time Genomics and certain royalty rights, will remain with Genesis “until value can be realised for shareholders,” it said.

Among other proposals put to genesis were ones that didn’t involve a continued presence in New Zealand, which the company said lacked comparative benefits to current shareholders. Genesis said it will update shareholders at their annual meeting on June 30.

Shares of Genesis, which was founded in 1994, last traded at 3.1 cents on May 18 and have slumped 74% in the past 12 months. They traded at more than $7.50 in early 2001.

The gene silencing research aims to deliver disease-curing payloads into human cells. It was turned down for additional funding from the Foundation for Research, Science and Technology.

Genesis said it is looking to transfer its royalty rights and equity interests in Solirna and Real Time Genomics into a separate entity, issuing shares to Genesis shareholders, who would also continue to hold existing stock.

Businesswire.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

SML - Synlait Milk Limited - Trading Halt of Securities
AIA - Auckland Airport announces board chair changes
AIA - Auckland Airport announces board chair changes
CEN - Tauhara commissioning progress update
FPH initiates voluntary limited recall
March 28th Morning Report
KFL Celebrates 20 Years of Excellence in Investment Mgmt.
SVR - Savor FY24 Earnings Guidance & Change in Banking Partner
NZK - NZ King Salmon Investments Limited FY24 Results
March 27th Morning Report